A5007353296- Atrial Fibrillation Management and Outcomes
- Acute Ischemic Stroke Management
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac Health and Mental Health
- Intracerebral and Subarachnoid Hemorrhage Research
- Cancer survivorship and care
- Cancer-related cognitive impairment studies
- Cardiac electrophysiology and arrhythmias
- Computational Drug Discovery Methods
- Cerebral Venous Sinus Thrombosis
- Heart Failure Treatment and Management
- Cardiovascular Issues in Pregnancy
- Adolescent and Pediatric Healthcare
- Venous Thromboembolism Diagnosis and Management
- Neurological Disorders and Treatments
- Cancer Treatment and Pharmacology
University of South Florida
2018-2023
Moffitt Cancer Center
2018-2021
Florida College
2021
Introduction: Precise risk of hemorrhagic transformation (HT) in acute ischemic stroke (AIS) remains unknown, leading to delays anticoagulation initiation for secondary prevention. We sought assess the rate HT associated with direct oral anticoagulant (DOAC) within and beyond 48 h post-AIS. Methods: A pooled analysis DOAC 14 days AIS or transient attack (TIA) was conducted six studies (four prospective open label treatment, blinded outcome two randomized trials; NCT02295826 NCT02283294). The...
It is unknown when to start anticoagulation after acute ischemic stroke (AIS) from atrial fibrillation (AF). Early may prevent recurrent infarctions but provoke hemorrhagic transformation as AF strokes are typically larger and transformation-prone. Later increases risk of secondary in this time frame. Our aim was compare early with apixaban patients or transient attack (TIA) versus warfarin administration at later intervals.AREST (Apixaban for Prevention Recurrent Embolic Stroke Hemorrhagic...
In clinical practice, reducing the burden of persistent atrial fibrillation by pharmacological means is challenging. We explored if blocking background and acetylcholine activated inward rectifier potassium currents (IK1 IKACh) could be antiarrhythmic in fibrillation. thus tested hypothesis that IK1 IKACh with chloroquine decreases used patch clamp to determine IC50 block molecular modeling simulate interaction between Kir2.1 Kir3.1, correlates IKACh. then tested, as a proof concept, oral...
Background: Optimal timing to initiate anticoagulation after Acute Ischemic Stroke (AIS) from Atrial Fibrillation (AF) is currently unknown. Compared other stroke etiologies, AF typically provokes larger infarct volumes and greater concern of hemorrhagic transformation, so seminal randomized trials waited weeks-to-months begin initial stroke. Subsequent data limited nonrandomized. Guidelines suggest initiation windows between 3 14 days post-stroke, with Class IIa recommendations, level...
Abstract Objective Women with breast cancer (BCA) and cardiovascular disease (CVD) risk factors are at increased of developing complications when exposed to potentially cardiotoxic therapy. The benefit aggressive CVD factor modification reduce adverse treatment-related psychologic biologic effects is not well established. Methods Using a single group pre-test, post-test design, 33 women BCA receiving anthracycline and/or trastuzumab therapy participated in 6-month comprehensive reduction...
The social determinants of health (SDoH) account for 80-90% modifiable contributors to outcomes chronic diseases such as heart failure. Knowledge gaps exist on how SDoH influences hospitalization rates in women with Our aim was evaluate the relationship between baseline status failure subsequent all-cause and cardiovascular hospitalization. This is a prospective observational longitudinal cohort study diagnosed 6 months follow-up. subjects completed assessment by Institute Medicine. Monthly...
Introduction The risk of hemorrhagic transformation (HT) in the early phase acute ischemic stroke (AIS) remains unknown, leading to potential unnecessary delays initiation anticoagulation for secondary prevention. We sought assess rate HT associated withdirect oral anticoagulant (DOAC) within and beyond 48 hours after AIS, using a pooled analysis available published data. Methods A 6 studies (4 prospective observational blinded outcome and2 randomized trials) DOAC 14 days AIS or transient...
Abstract Objective: Women with breast cancer (BCA) and cardiovascular disease (CVD) risk factors are at increased of developing complications when exposed to potentially cardiotoxic therapy. The benefit aggressive CVD factor modification reduce adverse treatment-related psychologic biologic effects is not well established. Methods: Using a single group pre-test, post-test design, 33 women BCA receiving anthracycline and/or trastuzumab therapy participated in 6-month comprehensive reduction...
Introduction: The burden of Atrial Fibrillation (AF) has previously been associated with a higher stroke risk in non-anticoagulated patients. We aim to find whether there is also an association between AF and recurrent cerebrovascular events anticoagulated patients after their initial acute ischemic (AIS) or transient attacks (TIA). Methods: AREST study (Apixaban for Early Prevention Recurrent Embolic Stroke Hemorrhagic Transformation) was multi-center, randomized controlled trial early...